<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596647</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2119</org_study_id>
    <secondary_id>2011-001489-16</secondary_id>
    <nct_id>NCT01596647</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of TKI258 on the Pharmacokinetics of Caffeine, Diclofenac, Omeprazole and Midazolam Administered as a Four-drug Cocktail in Patients With Advanced Solid Tumors, Excluding Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, phase I study to assess the effects of dovitinib (TKI258)&#xD;
      on the pharmacokinetics of a cocktail of caffeine, diclofenac, omeprazole and midazolam in&#xD;
      patients with advanced solid tumors, excluding breast cancer. The aim of this study is to&#xD;
      evaluate the potential effect of dovitinib (TKI258) on the metabolism of the probe drugs&#xD;
      caffeine, diclofenac, omeprazole and midazolam, which are metabolized by CYP1A2, CYP2C9,&#xD;
      CYP2C19 and CYP3A4 respectively (Cytochrome P450 isoenzyme), comparing the single-dose&#xD;
      pharmacokinetics (AUCtlast, AUCinf and Cmax parameters) of each of the individual probe drug&#xD;
      co-administered with and without multiple dose of dovitinib (TKI258) 500 mg under a 5 days on&#xD;
      / 2 days off dose schedule. The study foresees two treatment phases: DDI (drug-drug&#xD;
      interaction) followed by post-DDI. During the DDI phase patients receive treatment with the&#xD;
      probe drug cocktail and dovitinib (TKI258). During the post-DDI phase patients may continue&#xD;
      to receive treatment with dovitinib (TKI258) until disease progression (assessed by RECIST&#xD;
      1.1), unacceptable toxicity, death or discontinuation from the study treatment for any other&#xD;
      reason.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probe substrate pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters: AUCtlast (Area Under the Curve)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters: AUCinf</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters:Tmax (Time to maximum concentration)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters: HL (Half-life time)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters:CL/F (Apparent Oral Clearance)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate PK parameters:Vz/F (apparent volume of distribution)</measure>
    <time_frame>multiple time-points over 24h post dose on day 1 and Day 13 (DDI phase),</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs (Adverse Events)</measure>
    <time_frame>up to at least 30 days after the last dose of dovitinib (TKI258)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of antitumor activity of dovitinib (TKI258)</measure>
    <time_frame>every 8 weeks until progression of disease</time_frame>
    <description>overall response based on investigator's assessment and best overall response using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of SAEs (Serious Adverse Events)</measure>
    <time_frame>up to at least 30 days after the last dose of dovitinib (TKI258)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Advanced Solid Tumors, Excluding Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dovitinib, 5 days on / 2 days off dose schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam</description>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <other_name>probe drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam</description>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <other_name>probe drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam</description>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <other_name>probe drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam</description>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <other_name>probe drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <description>dovitinib, 5 days on / 2 days off dose schedule</description>
    <arm_group_label>TKI258 (dovitinib)</arm_group_label>
    <other_name>dovitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a cytopathologically or histopathologically confirmed diagnosis of an&#xD;
             advanced solid tumor, excluding breast cancer which has progressed despite standard&#xD;
             therapy or for which no standard therapy exists&#xD;
&#xD;
          -  ECOG performance status 0 or 1 and anticipated life expectancy â‰¥ 3 months&#xD;
&#xD;
          -  Patient must meet protocol-specific laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with brain metastases&#xD;
&#xD;
          -  Patients who have received or who are expected to receive any prohibited medications&#xD;
             and therapies&#xD;
&#xD;
          -  Patients who have received CYP1A2 inducer, CYP2C9/2C19 inducer or CYP3A4 inducer&#xD;
             medications within 30 days prior to start study treatment or are expected to receive&#xD;
             during the first 14 days after starting the study treatment&#xD;
&#xD;
          -  Patients with a known hypersensitivity to benzodiazepines&#xD;
&#xD;
          -  Patients who have not recovered from previous anti-cancer therapies&#xD;
&#xD;
          -  Patient with impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of TKI258&#xD;
&#xD;
          -  Patients who have concurrent severe and/or uncontrolled concomitant medical conditions&#xD;
             that could compromise participation in the study&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Fertile males or women not willing to use highly effective methods of contraception&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria will apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Cancer Center Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey Dept of Cancer Institute of NJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13883</url>
    <description>Results for CTKI258A2119 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer, tumors, phase I, drug-drug interaction, pharmacokinetic, probe drug, caffeine, diclofenac, omeprazole, midazolam, CYP1A2, CYP2C9, CYP2C19, CYP3A4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

